(0.01%) 5 479.25 points
(0.00%) 38 819 points
(0.06%) 19 933 points
(0.29%) $80.56
(1.15%) $2.82
(0.08%) $2 330.80
(-0.43%) $29.27
(-0.15%) $969.40
(0.03%) $0.932
(-0.10%) $10.64
(0.09%) $0.788
(-1.86%) $86.80
@ $55.46
Išleistas: 17 birž. 2024 @ 21:37
Grąža: 0.56%
Ankstesnis signalas: birž. 17 - 21:08
Ankstesnis signalas:
Grąža: -1.63 %
Live Chart Being Loaded With Signals
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1...
Stats | |
---|---|
Šios dienos apimtis | 705 980 |
Vidutinė apimtis | 954 947 |
Rinkos kapitalizacija | 3.69B |
EPS | $-0.590 ( Q1 | 2024-05-08 ) |
Kita pelno data | ( $-0.770 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-20.43 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $2.15 (3.86%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-10 | Shuman Harry | Sell | 500 | Share Option (right to buy) |
2024-06-12 | Shuman Harry | Sell | 2 000 | Share Option (right to buy) |
2024-06-12 | Shuman Harry | Buy | 2 000 | Common Shares |
2024-06-12 | Shuman Harry | Sell | 2 000 | Share Option (right to buy) |
2024-06-12 | Shuman Harry | Buy | 300 | Common Shares |
INSIDER POWER |
---|
82.36 |
Last 98 transactions |
Buy: 2 587 891 | Sell: 255 531 |
Tūris Koreliacija
Merus NV Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
YMAB | 0.925 |
VERA | 0.913 |
REYN | 0.913 |
HQY | 0.912 |
POWL | 0.904 |
HOWL | 0.903 |
LPLA | 0.901 |
MOR | 0.893 |
PEPG | 0.888 |
SLN | 0.883 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
SGML | -0.931 |
BIOL | -0.922 |
CNTY | -0.922 |
PRSO | -0.918 |
REVB | -0.915 |
MKTX | -0.911 |
OMCL | -0.911 |
DCOM | -0.91 |
RSLS | -0.909 |
WINT | -0.909 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Merus NV Koreliacija - Valiuta/Žaliavos
Merus NV Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $43.95M |
Bruto pelnas: | $-83.46M (-189.91 %) |
EPS: | $-3.00 |
FY | 2023 |
Pajamos: | $43.95M |
Bruto pelnas: | $-83.46M (-189.91 %) |
EPS: | $-3.00 |
FY | 2022 |
Pajamos: | $41.59M |
Bruto pelnas: | $29.60M (71.19 %) |
EPS: | $-2.92 |
FY | 2021 |
Pajamos: | $49.11M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.730 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Merus NV
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.